Castle Creek Biosciences, Inc.
Biotechnology ResearchPennsylvania, United States11-50 Employees
Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).